Neuroleptics with differential affinities at dopamine D2 receptors and sigma receptors affect differently the N-methyl-D-aspartate-induced increase in intracellular calcium concentration: Involvement of protein kinase

Synapse

Volumn 31, Issue 1, 1999, Pages 20-28

  Hayashi, Teruo ^a,b   Su, Tsung Ping ^a   Kagaya, Ariyuki ^b   Nishida, Akira ^c   Shimizu, Masami ^c   Yamawaki, Shigeto ^b  

^a Intramural Research Program   (United States)

^b HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^c NONE

Author keywords

Dopamine D2; Intracellular calcium; Neuroleptics; NMDA; PKA; Sigma receptor; Sulpiride

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; PROTEIN KINASE; SIGMA OPIATE RECEPTOR; SULPIRIDE;

ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; FRONTAL CORTEX; LIGAND BINDING; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; CALCIUM; CELLS, CULTURED; CHLORPROMAZINE; CLOZAPINE; DOPAMINE ANTAGONISTS; FRONTAL LOBE; GUANIDINES; HALOPERIDOL; N-METHYLASPARTATE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RECEPTORS, SIGMA; SULPIRIDE;

EID: 0032907911     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199901)31:1<20::AID-SYN4>3.0.CO;2-2     Document Type: Article

References (52)

1. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, Sandman CA, Bunney WE Jr, Jones EG. 1996. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16:19-30.
2. Aniline O, Pitts FN. 1982. Phencyclidine: a review and perspectives. Crit Rev Toxicol 10:145-177.
3. Cerne R, Rusin KI, Randic M. 1993. Enhancement of the N-methyl-D-aspartate response in spinal dorsal horn neurons by cAMP-dependent protein kinase. Neurosci Lett 161:124-128.
4. Chesselet MF, Delfs JM. 1996. Basal ganglia and movement disorders: An update. TINS 19:417-422.
5. Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T, Hidaka H. 1990. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinoline sulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 265:5267-5272.
6. 2+ induced by excitatory amino acids in CA1 hippocampal neurons. Science 240:649-653.
7. Cooper JK, Bloom FE, Roth RH. 1991. Dopamine. In: The biochemical basis of neuropharmacology. Oxford: Oxford UP, pp 285-337.
8. Coyle JT, Puttfarcken P. 1993. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262:689-694.
9. Deakin JFW, Slater P, Simpson MDC, Gilchrist AC, Skan WJ, Royston MC, Reynolds GP, Cross AJ. 1989. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 52:1781-1786.
10. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. 1989. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 12:1-13.
11. Fletcher EJ, MacDonald JF. 1993. Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurons. Eur J Pharmacol 235:291-295.
12. Gattaz WF, Schummer B, Behrens S. 1994. Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J Neural Transm Gen Sect 96:227-232.
13. Gerlach J. 1993. Pharmacology and clinical properties of selective dopamine antagonists with focus on substituted benzamides. In: Barnes T, editor. Antipsychotic drugs and their side-effects. London: Academic Press, pp 45-63.
14. Greengard P, Jen J, Nairn AC, Stevens CF. 1991. Enhancement of the glutamate response by cAMP-dependent protein kinase in hippocampal neurons. Science 253:1135-1138.
15. 2+ mobilization by N-methyl-D-aspartate in primary culture of rat frontal cortical neurons. J Pharmacol Exp Ther 275:207-214.
16. Hellewell SB, Bowen WD. 1990. A sigma-like binding site in rat pheochromocytoma (PC12) cells: Decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res 527:244-253.
17. Hollmann M, Heinemann S. 1994. Cloned glutamate receptors. Annu Rev Neurosci 17:31-108.
18. Huang CC, Gean PW. 1995. Cyclic adenosine-3′, 5′-monophosphate potentiates the synaptic potential mediated by NMDA receptors in the amygdala. J Neurosci Res 40:747-754.
19. Kerwin RW, Patel S, Meldrum BS, Czudek C, Reynolds GP. 1988. Asymmetrical loss of glutamate receptor sub-type in left hippocampus in schizophrenia. Lancet 1:583-584.
20. Kitamura Y, Miyazaki A, Yamanaka Y, Nomura Y. 1993. Stimulatory effects of protein kinase C and calmodulin kinase II on N-methyl-D-aspartate receptor/channels in the postsynaptic density of rat brain. J Neurochem 61:100-109.
21. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 77:231-236.
22. Korpi ER, Kleinman JE, Goodman SI, Wyatt RJ. 1987. Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients. Psychiatry Res 22:291-301.
23. Law-Tho D, Hirsch JC, Crepel F. 1994. Dopamine modulation of synaptic transmission in rat prefrontal cortex: An in vitro electrophysiological study. Neurosci: Res 21:151-160.
24. Lazarewicz JW, Wroblewski JT, Palmer ME, Costa E. 1988. Activation of N-methyl-D-aspartate-sensitive glutamate receptors stimulates arachidonic acid release in primary cultures of cerebellar granule cells. Neuropharmacol 27:765-769.
25. Luo JH, Wang YH, Yasuda RP, Wolfe BB. 1996. The majority of cortical NMDA receptors contain three subunits (NMDAR1/2A/2B). FASEB J 10:A141.
26. 25-35-amyloid peptide. Neuroscience 83:428-443.
27. Meshul CK, Stallbaumer RK, Tayler B, Janowsky A. 1994. Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res 648:181-195.
28. Meshul CK, Bunker GL, Mason JN, Allen C, Janowsky A. 1996. Effect of subchronic clozapine and haloperidol on striatal glutamatergic synapses. J Neurochem 67:1965-1973.
29. Moghaddam B. 1994. Recent basic findings in support of excitatory amino acid hypotheses of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 18:859-870.
30. Monnet FP, Debonnel G, DeMontigny C. 1992. In vivo electrophysiological evidence for a selective modulation of N-methyl-D-aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by sigma ligands. J Pharmacol Exp Ther 261:123-130.
31. Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, Seeburg PH. 1992. Heteromeric NMDA receptors: Molecular and functional distinction of subtypes. Science 256:1217-1221.
32. Morris RGM, Davis S, Butcher SP. 1989. The role of NMDA receptors in learning and memory. In: Watkins JC, Collingridge GL, editors. The NMDA receptor. Oxford: Oxford University Press, pp 137-151.
33. 3H-kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett 40:245-250.
34. Perry TL, Hansen S, Jones K. 1989. Schizophrenia tardive dyskinesia and brain GABA. Biol Psychiatry 25:200-206.
35. Peterson RC, Stillman RC. 1978. Phencyclidine: An overview. In. Phencyclidine abuse: An appraisal. National Institute of Drug Abuse Research Monograph 21:1-7.
36. Raman IM, Tong G, Jahr CE. 1996. Beta-adrenergic regulation of synaptic NMDA receptors by cAMP-dependent protein kinase. Neuron 16:415-421.
37. Simpson MD, Slater P, Royston MC, Deakin JF. 1991. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effect of disease process and neuroleptic medication. Schizophr Res 6:41-48.
38. Sokoloff P, Schwartz JC. 1995. Novel dopamine receptors half a decade later. TiPS 16:270-275.
39. 3) as a target for neuroleptics. Nature 347:146-151.
40. 3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther 223:284-290.
41. Su T-R 1991. σ receptors; Putative links between nervous, endocrine and immune systems. Eur J Biochem 200:633-642.
42. Su T-P, London ED, Jaffe JH. 1988. Steroid binding at σ receptors suggests a link between endocrine, nervous, and immune systems. Science 240:219-221.
43. Tam SW. 1983. Naloxone-inaccessible sigma receptor in rat central nervous system. Proc Natl Acad Sci USA 80:6703-6707.
44. 3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA 81:5618-5621.
45. Toru M, Watanabe S, Shibuya H. 1988. Neurotransmitters, receptors and neuropeptides in post-mortem brains of schizophrenic patients. Acta Psychiatr Scand 78:121-137.
46. Toyoda H, Takahata R, Inayama Y, Sakai J, Matsumura H, Yoneda H, Asaba H, Sakai T. 1997. Effect of antipsychotic drugs on the gene expression of NMDA receptor subunits in rat. Neurochem Res 22:249-252.
47. 3H](+)SKF-10047 binding to sigma receptors. Eur J Pharmacol 311:R1-R2.
48. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-619.
49. Winn P. 1994. Schizophrenia research moves to the prefrontal cortex. TINS 17:265-268.
50. Wu X-Z, Bell JA, Spivak CE, London EL, Su T-P. 1991. Electrophysiological and binding studies on intact NCB-20 cells suggest presence of a low affinity sigma receptors. J Pharmacol Exp Ther 257:351-359.
51. Yang B, Wang Y, Cynader MS. 1996. Synergistic interactions between noradrenaline and glutamate in cytosolic calcium influx in cultured visual cortical neurons. Brain Res 721:181-190.
52. Yoshida Y, Ono T, Kawano K, Miyagishi T. 1994. Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate putamen. Brain Res 639:139-148.